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Adjunctive therapeutic strategies that modulate the inflammatory mediators can play a significant role in periodontal therapy. In this
double-blind, placebo-controlled study, 60 subjects diagnosed as periodontitis patients were evaluated for 28 days after periodontal
treatment combined with selective cyclooxygenase-2 (COX-2) inhibitor. The experimental group received scaling and root planning
(SRP) combined with the Loxoprofen antiinflammatory drug (SRP+Loxoprofen). The control group received SRP combined with
placebo (SRP+placebo). Plaque index (PI), probing pocket depth (PD) and bleeding on probing (BOP) were monitored with an
electronic probe at baseline and after 14 and 28 days. Both groups displayed clinical improvement in PD, PI and BOP. They also
showed statistically similar values (p>0.05) of PD reduction on day 14 (0.4 mm) and on day 28 (0.6 mm). At the baseline, few deeper
sites (7 mm) from SRP+Loxoprofen group were responsible and most PD reduction was observed after 14 days (p<0.05). The
percentage of remaining deep pockets 7 mm) after 14 days in the SRP+Loxoprofen group was significantly lower (p<0.05) than in
the SRP+placebo group. Loxoprofen presents potential effect as an adjunct of periodontal disease treatment, but long-term clinical
trials are necessary to confirm its efficacy.
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INTRODUCTION
Periodontal disease is a high prevalent infectious
injury caused by specific bacterial species. However,
most of the tissue breakdown is indirectly caused by toxic
bacterial products that trigger the host response. Host-
derived enzymes known as matrix metalloproteinases
(MMPs), changes in osteoclast activity by cytokines and
other inflammatory mediators like prostanoids are respon-
sible for most periodontal tissue destruction (1). The
cyclooxygenase (COX) products of the arachidonic
acid or simply prostanoids (PGs) and tromboxane
(TxB2) are produced by activated monocytes, platelets
and fibroblasts. Both PGs and TxB2 are strong vasoac-
tive mediators and stimulators of bone resorption (1-3).
Several host modulatory agents have been inves-
tigated in clinical trials. Non-steroidal antiinflammatory
drugs (NSAIDs), sub-antimicrobial dose of doxycy-
cline and bisphosphonates or combination of drugs have
been successfully used as an adjunct to non-surgical
mechanical periodontal therapy. The results of host
modulation studies have shown that this approach may
be a potential target to reduce tissue destruction. NSAIDs
blockade the pro-inflammatory cytokines; sub-dose of
doxycycline blockades the metalloproteinases and the
bisphosphonates blockade the osteoclast activity (4,5).
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The basis of antiinflammatory drugs in periodon-
tal disease treatment is related to the control of prostag-
landin E2 (PGE2) through the inhibition of
cyclooxygenase-2 (COX-2) enzyme. Higher levels of
PGE2 are associated with increased gingival inflamma-
tion and alveolar bone loss (1,3,6,7). Therefore, the
purpose of this study was to evaluate a selective COX-
2 inhibitor derived from phenylpropionic acid,
Loxoprofen sodium, as an adjunct for periodontal dis-
ease treatment, using probing pocket depth (PD) to
verify the inflammation reduction.
MATERIAL AND METHODS
Sample Distribution and Study Design
This was a randomized, double-blind, placebo-
controlled study, which used parallel inter-subjects and
a split-mouth design. Sixty healthy non-smoking sub-
jects with at least 20 teeth, ranging in age from 35-50
years, who had two or more teeth with clinical attach-
ment loss (CAL) 6 mm and one or more sites with PD
5 mm were selected according to the established
periodontitis criteria. Exclusion criteria were: presence
of systemic diseases, pregnancy or nursing women,
gastric ulcer, hypersensitivity to antiinflammatory drugs,
use of antibiotic, corticoids, immunosuppressive drugs
or any NSAIDs within the past three months.
The 60 patients were randomly assigned to
experimental and control groups. The experimental
group received periodontal treatment that consisted of
conventional scaling and root planning (SRP), using
ultrasonic scaler (Bob-Cat, Dentsply/Cavitron, Long
Island City, NY, USA) and Gracey curettes (Hu-Friedy,
Chicago, IL, USA) combined with 60 mg/day of
Loxoprofen (Loxonin; Sankyo Pharma Brasil Ltda,
Barueri, SP, Brazil) during 28 days (SRP+Loxoprofen).
The control group received the same SRP treatment
combined with placebo (SRP+Placebo). Periodontal
treatment was performed in 2 phases by a blinded
experienced periodontist (BP). Randomly, half-mouth
received one-session of SRP at the baseline and the
contra-lateral side of the mouth received one-session of
SRP on day 14 (Fig. 1).
Clinical Procedures, Measurements and Monitoring
At baseline, medical and dental histories were
recorded and the following clinical parameters were
measured: PD measured at 6 sites/teeth using an elec-
tronic probe (Florida Probe Corporation, Gainesville, Fl,
USA); the percentage of sites with bleeding on probing
(BOP) and the percentage of tooth surfaces with dental
plaque (PI) (Table 1). The patients received mechanical
therapy (SRP), oral hygiene instruction and orientation
about medication. Coded medication or placebo pack-
ages were supplied for the first 14 days. Then, at the
second appointment, clinical measurements were re-
corded and drug use was assessed by means of medi-
cation package inspection and pills counting. Also, oral
hygiene instruction was reinforced and the contra-
lateral side of the mouth received SRP. Mechanical
therapy was completed and the remaining medication or
placebo packages were supplied for the next 14 days. At
the end of 28 days, all clinical measurements were re-
taken by the same blinded operator and medication use
was reviewed.
Statistical Analysis
The clinical measurements per patient were as-
sessed. The mean and standard deviations were calcu-
lated and non-parametric analyses were performed
using statistical software (Statistica for Window;
StatSoft, Inc., Tulsa, OK, USA). The number of sites
Figure 1. Study design and timeline. All 60 patients had their
clinical measurements recorded at baseline, 14 and 28 days.
Scaling and root planning was performed in 2 sessions, half-
mouth at the baseline and the remaining contra-lateral teeth after
14 days. Two groups were determined based on the Loxoprofen
or placebo intake as an adjunct to the non-surgical periodontal
therapy. Loxoprofen dosage was 60 mg/day during 28 days.
Placebo pills were identical to the real medication to keep the
patients and operator blinded. Probing pocket depth (PD),
Bleeding on probing (BP) and Plaque index (PI).
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with initial PD < 4 mm, 4 < 7 mm and 7 mm per patient
were computed for further analysis. Mann-Whitney
test was used to compare the differences between
groups (SRP+Loxoprofen and SRP+Placebo). Fried-
man test compared differences among the time points
(baseline, 14 and 28 days) in each group. Chi-square
test was used for nominal variables. All statistical
analysis considered the significant level of 5%. The
Cohen’s d effect size was also calculated for further
interpretation of the observed statistical significance.
RESULTS
All 60 patients completed the study, presenting
100% of medication compliance or placebo, and no
complain of adverse reactions to the Loxoprofen therapy.
Compliance was monitored at both recall and final exam
visits by the assessment of the amount of medication
taken from the original prescription package.
Baseline demographic characteristics of the pa-
tients divided by groups are presented in Table 1. There
were no statistically significant differences (p>0.05)
between groups regarding the evaluated parameters at
baseline. The smaller and uniform amount of plaque
recorded in both groups after 14 and 28 days suggest
Table 1. Baseline parameters for SRP+Loxoprofen and
SRP+Placebo groups. No statistically significant differences were
observed between groups (p>0.05). Patients received the
periodontal treatment according to a random order (n=60). The
randomization was assured due to the arbitrary distribution of
the coded medication or placebo.
Parameters Groups
SRP+Loxoprofen SRP+Placebo
Age (yrs) 41 ± 4 42 ± 5
Age range 35-49 35-50
Gender (male /female) 14/16 14/16
Race (whites/non-whites) 21/9 18/12
PD (mm) 2.6 ± 0.6 2.4 ± 0.6
BP (%) 23.8 ± 10.0 23.6 ± 11.1
PI (%) 61.0 ± 25.4 68.0 ± 27.0
PD = Probing pocket depth; BOP = Bleeding on probing; PI=
Plaque index.
the high degree of patient compliance with the proposed
protocol.
The therapeutic approach used in this study,
SRP+Loxoprofen or SRP+Placebo, promoted clinical
improvement with statistically significant reduction
(p<0.05) of PD and BOP during the evaluated intervals
(between 0-14, 0-28 and 14-28 days). Regarding PI,
the reduction was statistically significant (p<0.05)
between 0-14 and 0-28 days, but not between 14-28
days (p>0.05).
Although both groups showed clinical improve-
ment, there were no statistically significant differences
(p>0.05) in PD reduction between groups after 28
days. SRP+Loxoprofen and SRP+Placebo groups
showed a PD reduction of 0.4 mm on day 14. After 28
days, the overall PD reduction for both groups was 0.6
mm (p>0.05).
Comparative analyses of the sites that did not
receive SRP therapy in the first 14 days showed greater PD
reduction than the control sites (no-SRP+placebo). This
difference was statistically significant (p<0.05) after 14
days, suggesting the potential effect of the adjunctive
therapy, although not clinically relevant. PD reduction
mean was 0.3 ± 1.0 mm for Loxoprofen therapy solely and
0.2 ± 1.1 mm for control sites. On day 14, both groups
received SRP at the contra-lateral side of the mouth
followed by supplementary dose of medication or placebo
for the next 14 days.
Considering the patient as an experimental unit,
there was no significant difference (p>0.05) in the PD
reduction between patients that used the medication and
those that received placebo. The differences were not
statistically significant neither after 14 days nor after 28
days of periodontal treatment combined with adjunctive
antiinflammatory therapy (p>0.05). On day 14, the PD
reduction in sites with initial PD 7 mm, in the
SRP+Loxoprofen group, (2.2 ± 2.0 mm) was statistically
greater than in the SRP+placebo group (1.5 ± 1.8 mm)
(p<0.05).
Figure 2 demonstrated that after 14 days, the
remaining deep pockets 7 mm of the SRP+Loxoprofen
group was significantly lower than in the SRP+placebo
group (p<0.05). However, the effect size for the PD
reduction observed in the study was very low (d<0.4),
indicating that the result is not clearly relevant. After 28
days, there were no statistically significant differences
(p>0.05) in PD reduction among groups and the percent-
age of remaining deep pockets were similar.
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DISCUSSION
This short-term study evaluated the effect of
Loxoprofen on the reduction of probing pocket depth.
It was observed a limited suggestive potential for the
treatment of deep periodontal pockets. Nevertheless,
the initial difference in PD reduction and the benefits on
the deeper periodontal pockets were insignificant after
28 days or longer. Likewise, other studies (2,8,9) have
found no differences in PD reduction between placebo
and NSAID group after 28 days.
When the PD reduction was evaluated consider-
ing the initial measurements of PD, the deeper periodon-
tal pockets showed additional improvement in the first
14 days after the SRP+Loxoprofen therapy. Moreover,
in the SRP+Loxoprofen group the percentage of re-
maining periodontal pockets 7 mm was significantly
reduced after 14 days, indicating some limited but
potential effect of the adjunctive therapy on the early
stage of periodontal treatment. Significant reduction of
PGF2 and PGE2 in the gingival tissue levels was
observed in the first 10 days after mechanical therapy
combined with NSAID adjunctive treatment (2). These
findings suggest that the antiinflammatory effect and
subsequent PD reduction is more evident in the early
phase of the adjunctive therapy (8).
Overall, no significant differences were observed
in PD reduction but in deep periodontal pockets (PD 7
mm). This can probably be explained by the fact that
localized site measurements produce mean values that
do not adequately represent the periodontal disease of
the entire mouth. The larger number of healthy sites
obscures a few deeper sites, commonly found in chronic
periodontitis, since the limited amount of deep pockets
might not influence the general result. Multi-level data
analysis considering inter-dependent variables are help-
ful but require advanced resources (10).
In addition, the demonstration of additional ben-
efits of any adjunctive therapy for periodontitis treat-
ment needs adequate study designs. Clinical improve-
ment is usually obtained due to a successful mechanical
therapy and thus, only a small effect can be attributed to
the adjunctive therapy. The lack of difference in PI
reduction between groups, after 14 and 28 days, and the
clinical improvement in the control group support the
idea that most of the clinical benefits frequently come
from conventional therapy associated to an effective
plaque control. Therefore, even under medication, some
Figure 2. Percentage of sites on the different time-points according
to the probing pocket depth (PD). Panel A = shows the increasing
number of shallow periodontal pockets (< 4 mm) over 14 and 28
days. No statistically significant differences (p>0.05) were
observed for this PD sites. Panel B = shows that the periodontal
pockets 4 < 7 mm presented a reduction tendency over time. In
Panel C, there is a significant difference (p<0.05) in the percentage
of deep periodontal pocket (7 mm) between groups on day 14.
The SRP+Loxoprofen therapy promoted faster reduction in the
number of the deep periodontal pockets but no difference was
observed after 28 days.
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degree of inflammation and PD reduction may be related
to patient motivation and cooperation (11). The out-
comes of the present study are supported by investiga-
tions using NSAIDs for experimental gingivitis treat-
ment (8,12).
Regarding NSAID efficacy period, it has been
shown that the inhibitory effect of PGE2 continues only
during drug intake phase and will end after drug therapy
cessation (13). In this short-term evaluation, PD and
BOP presented significant improvement during the
observation period. However, no differences were de-
tected between groups on day 28, which indicate that
mechanical therapy alone or combined with Loxoprofen
can successfully reduce the inflammation and promote
pocket depth reduction. Therefore, the extended use of
NSAIDs as an adjunctive therapy is not essential to
reduce gingival inflammation and should be limited to
the active phases of periodontal disease.
The long-term use of NSAIDs has been revisited
by US Food and Drug Administration (FDA). FDA
reported that the widely use of a high-selective COX-2
inhibitor for more than 18 months induces risk of heart
attack and stroke (14). This fact may be explained by the
effect of coxibs on the inhibition of endothelial prostacyclin
(PGI2) synthesis. PGI2 prevents platelet aggregation and
causes vasodilatation. These effects contrast with platelet
COX-1-derived thromboxane A2 (TxA2), which causes
platelet aggregation, vasoconstriction and vascular pro-
liferation. Thus, selective  COX-2 blockade favors TxA2
and potentially pre-disposes patient to hypertension,
heart attack and stroke (15).
One limitation of this study is the lack of bio-
chemical analyses of the gingival crevicular fluid (GCF)
and tissue biopsy. Nevertheless, although PGs levels of
the patients were not measured in this experiment, it
seems like the present findings are related to the mecha-
nism of the COX-2 inhibition and are supported by
previous studies (7-9,12,16).
The effects of NSAIDs on PGE2 levels (2,13),
gingival inflammation (17) and alveolar bone loss
(16,18,19) have been widely examined in human, animal
and in vitro experiments (6,20). In general, the results
have shown beneficial effect the early phase of peri-
odontal treatment, gingivitis and prevention of bone
loss. However, the variety of the results found in the
literature can be attributed to differences in the study
designs, dosage and duration of NSAID therapy, and the
selectivity of NSAID to COX-2 (1).
The NSAID used in this study (Loxoprofen) is
more selective to COX-2 than COX-1 and demonstrated
a limited advantage when compared to placebo, com-
bined or not to the mechanic therapy. However, the
clinical significance may be questioned and the indica-
tion of this medicament should be restricted to clinical
situations where deep pockets are present. Conse-
quently, the prescription of Loxoprofen as an adjunct
for the non-surgical mechanical therapy may have an
indication on the early stages of the treatment of
advanced forms of periodontal diseases. Further inves-
tigations in selected patients may elucidate this potential
indication.
The following conclusions can be drawn: 1.
adjunctive antiinflammatory therapy may lead to a faster
and greater probing pocket depth reduction than con-
ventional periodontal therapy; 2. health condition should
be carefully evaluated before recommending Loxoprofen
as an adjunct for clinical use; 3. Loxoprofen antiinflam-
matory drug presents potential effect as an adjunct of
periodontal disease treatment, but long-term clinical
trials are necessary to confirm its efficacy.
RESUMO
Estratégias terapêuticas adjuvantes que modulam os mediadores
inflamatórios podem ter função significante na terapia periodon-
tal. Neste estudo duplo-cego controlado com placebo, 60
indivíduos diagnosticados com periodontite foram avaliados por
28 dias após tratamento periodontal combinado com inibidor
seletivo de COX-2. O grupo experimental foi tratado com
raspagem e alisamento radicular combinado com medicação anti-
inflamatória Loxoprofeno (RAR+Loxoprofen). O grupo controle
foi tratado com raspagem e alisamento radicular combinado com
medicação placebo (Raspagem e alisamento radicular -
RAR+placebo). Presença de placa (PI), profundidade de sondagem
(PS) e sangramento à sondagem (SS) foram monitoradas com
auxílio de uma sonda computadorizada no início do estudo e após
14 e 28 dias. Os dois grupos demonstraram melhora clínica em
relação a PS, PI e SS. Também foi observado valores semelhantes
(p>0,05) de redução da PS nos períodos de 14 dias (0,4 mm) e 28
dias (0,6 mm). No início do estudo, alguns sítios profundos (7
mm) do grupo RAR+Loxoprofen foram os responsáveis pela
maior redução da PS depois de 14 dias (p<0,05). A porcentagem
de bolsas periodontais profundas 7 mm após 14 dias no grupo
RAR+Loxoprofen foi significativamente inferior do que o grupo
RAR+placebo (p<0.05). A medicação Loxoprofen apresenta
potencial efeito adjuvante à terapia periodontal, mas estudos de
longo prazo são necessários para confirmar sua eficácia.
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